Monique M Ryan

List of Publications by Year
in descending order

		87888	85541
145	6,028	38	71
papers	citations	h-index	g-index

147	147	147	8063
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscular Disorders, 2019, 29, 842-856.	0.6	401
2	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	13.7	365
3	Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 2014, 50, 477-487.	2.2	357
4	A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genetics in Medicine, 2016, 18, 1090-1096.	2.4	332
5	Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet, The, 2018, 391, 451-461.	13.7	306
6	Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain, 2010, 133, 1810-1822.	7.6	268
7	Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nature Genetics, 2012, 44, 704-708.	21.4	216
8	Neurofilament as a potential biomarker for spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2019, 6, 932-944.	3.7	137
9	Ascorbic acid for Charcotâ€“Marieâ€“Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurology, The, 2009, 8, 537-544.	10.2	131
10	Pathophysiological Mechanisms of Dominant and Recessive GLRA1 Mutations in Hyperekplexia. Journal of Neuroscience, 2010, 30, 9612-9620.	3.6	112
11	EPG5-related Vici syndrome: a paradigm of neurodevelopmental disorders with defective autophagy. Brain, 2016, 139, 765-781.	7.6	99
12	Evolution of foot and ankle manifestations in children with CMT1A. Muscle and Nerve, 2009, 39, 158-166.	2.2	96
13	Next generation sequencing in a large cohort of patients presenting with neuromuscular disease before or at birth. Orphanet Journal of Rare Diseases, 2015, 10, 148.	2.7	94
14	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	5.3	93
15	An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. Journal of Neurology, 2015, 262, 1344-1353.	3.6	89
16	Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscular Disorders, 2000, 10, 398-406.	0.6	87
17	Natural history of pulmonary function in collagen VI-related myopathies. Brain, 2013, 136, 3625-3633.	7.6	85
18	Pontocerebellar hypoplasia type 1. Neurology, 2013, 80, 438-446.	1.1	84

#	Article	IF	Citations
19	Histopathological Findings in Hereditary Motor and Sensory Neuropathy of Axonal Type With Onset in Early Childhood Associated WithMitofusin 2Mutations. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1097-1102.	1.7	81
20	Critical illness polyneuropathy and myopathy in pediatric intensive care: A review. Pediatric Critical Care Medicine, 2007, 8, 18-22.	0.5	75
21	Loss of function of SLC25A46 causes lethal congenital pontocerebellar hypoplasia. Brain, 2016, 139, 2877-2890.	7.6	74
22	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research, 2018, 136, 140-150.	7.1	69
23	Guillain-Barre syndrome in childhood. Journal of Paediatrics and Child Health, 2005, 41, 237-241.	0.8	66
24	A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene. Human Molecular Genetics, 2013, 22, 1404-1416.	2.9	64
25	Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology, 2019, 93, e1312-e1323.	1.1	64
26	Auditory function in children with Charcot-Marie-Tooth disease. Brain, 2012, 135, 1412-1422.	7.6	63
27	Dietary L-Tyrosine Supplementation in Nemaline Myopathy. Journal of Child Neurology, 2008, 23, 609-613.	1.4	58
28	De Novo Truncating Mutations in AHDC1 in Individuals with Syndromic Expressive Language Delay, Hypotonia, and Sleep Apnea. American Journal of Human Genetics, 2014, 94, 784-789.	6.2	57
29	Health-related Quality of Life in Boys With Duchenne Muscular Dystrophy: Agreement Between Parents and Their Sons. Journal of Child Neurology, 2010, 25, 1188-1194.	1.4	55
30	Pediatric Guillain-BarrÃ© syndrome. Current Opinion in Pediatrics, 2013, 25, 689-693.	2.0	53
31	Neurophysiologic abnormalities in children with Charcotâ€Marieâ€Tooth disease type 1A. Journal of the Peripheral Nervous System, 2008, 13, 236-241.	3.1	49
32	Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. Frontiers in Neurology, 2019, 10, 898.	2.4	49
33	NEMF mutations that impair ribosome-associated quality control are associated with neuromuscular disease. Nature Communications, 2020, 11, 4625.	12.8	47
34	Acute Transverse Myelitis and Acute Disseminated Encephalomyelitis in Childhood: Spectrum or Separate Entities?. Journal of Child Neurology, 2009, 24, 287-296.	1.4	46
35	Nusinersen for SMA: expanded access programme. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 937-942.	1.9	46
36	Hand involvement in children with Charcotâ€“Marie-Tooth disease type 1A. Neuromuscular Disorders, 2008, 18, 970-973.	0.6	44

#	Article	IF	Citations
37	The use of invasive ventilation is appropriate in children with genetically proven spinal muscular atrophy type 1: the motion against. Paediatric Respiratory Reviews, 2008, 9, 51-54.	1.8	44
38	Peripheral nerve ultrasound in pediatric Charcot-Marie-Tooth disease type 1A. Neurology, 2015, 84, 569-574.	1.1	42
39	Efficacy and safety of vamorolone in Duchenne muscular dystrophy:ÂAn 18-month interim analysis of a non-randomized open-label extension study. PLoS Medicine, 2020, 17, e1003222.	8.4	41
40	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	1.4	41
41	A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy. European Journal of Human Genetics, 2015, 23, 1294-1300.	2.8	39
42	Reliability of quantifying foot and ankle muscle strength in very young children. Muscle and Nerve, 2008, 37, 626-631.	2.2	36
43	Diagnostic and cost utility of whole exome sequencing in peripheral neuropathy. Annals of Clinical and Translational Neurology, 2017, 4, 318-325.	3.7	36
44	Effect of Oral Curcumin on DÃ©jÃ©rine-Sottas Disease. Pediatric Neurology, 2009, 41, 305-308.	2.1	35
45	Describing nutrition in spinal muscular atrophy: A systematic review. Neuromuscular Disorders, 2016, 26, 395-404.	0.6	35
46	â€˜A short time but a lovely little short timeâ€™: Bereaved parents' experiences of having a child with spinal muscular atrophy type 1. Journal of Paediatrics and Child Health, 2016, 52, 40-46.	0.8	32
47	Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Annals of Clinical and Translational Neurology, 2022, 9, 339-350.	3.7	32
48	CMTX mimicking childhood chronic inflammatory demyelinating neuropathy with tremor. Muscle and Nerve, 2005, 31, 528-530.	2.2	31
49	Paralysis and a perihilar protuberance: An unusual presentation of sarcoidosis in a child. Pediatric Pulmonology, 2009, 44, 410-414.	2.0	31
50	MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability. Brain, 2017, 140, 2093-2103.	7.6	31
51	The severe epilepsy syndromes of infancy: A populationâ€based study. Epilepsia, 2021, 62, 358-370.	5.1	31
52	Spinal muscular atrophy type 1: Is long-term mechanical ventilation ethical?. Journal of Paediatrics and Child Health, 2007, 43, 237-242.	0.8	30
53	Physician attitudes towards ventilatory support for spinal muscular atrophy type 1 in Australasia. Journal of Paediatrics and Child Health, 2007, 43, 790-794.	0.8	30
54	Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene. Annals of Neurology, 2007, 62, 422-426.	5.3	29

#	Article	IF	Citations
55	Complete callosal agenesis, pontocerebellar hypoplasia, and axonal neuropathy due to AMPD2 loss. Neurology: Genetics, 2015, 1, e16.	1.9	29
56	A diagnostic approach to recurrent myalgia and rhabdomyolysis in children. Archives of Disease in Childhood, 2015, 100, 793-797.	1.9	29
57	Anterior horn cell disease and olivopontocerebellar hypoplasia. Pediatric Neurology, 2000, 23, 180-184.	2.1	28
58	Health status of boys with Duchenne muscular dystrophy: A parent's perspective. Journal of Paediatrics and Child Health, 2011, 47, 557-562.	0.8	27
59	Genetic axonal neuropathies and neuronopathies of preâ€natal and infantile onset. Journal of the Peripheral Nervous System, 2012, 17, 285-300.	3.1	26
60	Interventions for the prevention and treatment of pes cavus. The Cochrane Library, 2007, , CD006154.	2.8	25
61	Development and validation of the Charcot-Marie-Tooth Disease Infant Scale. Brain, 2018, 141, 3319-3330.	7.6	25
62	Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric charcotâ€“marieâ€“tooth disease type 1A. Muscle and Nerve, 2010, 42, 262-267.	2.2	24
63	Genetic, Radiologic, and Clinical Variability in Brown-Vialetto-van Laere Syndrome. Seminars in Pediatric Neurology, 2018, 26, 2-9.	2.0	24
64	Strong Correlation Between the 6-Minute Walk Test and Accelerometry Functional Outcomes in Boys With Duchenne Muscular Dystrophy. Journal of Child Neurology, 2015, 30, 357-363.	1.4	22
65	Quality of Life in Children With Charcot-Marie-Tooth Disease. Journal of Child Neurology, 2010, 25, 343-347.	1.4	21
66	Unraveling the pathogenesis of ARX polyalanine tract variants using a clinical and molecular interfacing approach. Molecular Genetics & Genomic Medicine, 2015, 3, 203-214.	1.2	21
67	DCC Is Required for the Development of Nociceptive Topognosis in Mice and Humans. Cell Reports, 2018, 22, 1105-1114.	6.4	21
68	Whole Genome Sequencing Identifies a 78 kb Insertion from Chromosome 8 as the Cause of Charcot-Marie-Tooth Neuropathy CMTX3. PLoS Genetics, 2016, 12, e1006177.	3.5	20
69	Childhood Chronic Inflammatory Demyelinating Polyneuropathy. Journal of Child Neurology, 2014, 29, 43-48.	1.4	19
70	Deterioration in gait and functional ambulation in children and adolescents with Charcotâ€“Marieâ€“Tooth disease over 12 months. Neuromuscular Disorders, 2017, 27, 658-666.	0.6	19
71	Importance of muscle biopsy to establish pathogenicity of DMD missense and splice variants. Neuromuscular Disorders, 2019, 29, 913-919.	0.6	19
72	Cardiac phenotype in ATP1A3 -related syndromes. Neurology, 2020, 95, e2866-e2879.	1.1	19

#	Article	IF	Citations
73	Neuronal ceroid lipofuscinosis type 2: an Australian case series. Journal of Paediatrics and Child Health, 2020, 56, 1210-1218.	0.8	19
74	High resolution chromosomal microarray in undiagnosed neurological disorders. Journal of Paediatrics and Child Health, 2013, 49, 716-724.	0.8	18
75	A multinational study on motor function in early-onset FSHD. Neurology, 2018, 90, e1333-e1338.	1.1	17
76	International retrospective natural history study of LMNA-related congenital muscular dystrophy. Brain Communications, 2021, 3, fcab075.	3.3	17
77	Epidermolysis bullosa with lateâ€onset muscular dystrophy and plectin deficiency. Muscle and Nerve, 2011, 44, 135-141.	2.2	16
78	Autoimmune myasthenia gravis, immunotherapy and thymectomy in children. Neuromuscular Disorders, 2012, 22, 118-121.	0.6	16
79	Powered standing wheelchairs promote independence, health and community involvement in adolescents with Duchenne muscular dystrophy. Neuromuscular Disorders, 2019, 29, 221-230.	0.6	16
80	A homozygous UBA5 pathogenic variant causes a fatal congenital neuropathy. Journal of Medical Genetics, 2020, 57, 835-842.	3.2	16
81	Current Therapeutic Strategies for Patients With Polyneuropathies Secondary to Inherited Metabolic Disorders. Mayo Clinic Proceedings, 2003, 78, 858-868.	3.0	15
82	Energy metabolism and mitochondrial defects in X-linked Charcot-Marie-Tooth (CMTX6) iPSC-derived motor neurons with the p.R158H PDK3 mutation. Scientific Reports, 2020, 10, 9262.	3.3	15
83	Atypical Silverâ€"Russell phenotype resulting from maternal uniparental disomy of chromosome 7. American Journal of Medical Genetics, Part A, 2010, 152A, 2342-2345.	1.2	14
84	Demyelinating prenatal and infantile developmental neuropathies. Journal of the Peripheral Nervous System, 2012, 17, 32-52.	3.1	14
85	Recessive MYH7-related myopathy in two families. Neuromuscular Disorders, 2019, 29, 456-467.	0.6	14
86	Feasibility of a Computerized Method to Measure Quality of â€œEverydayâ€•Life in Children with Neuromuscular Disorders. Physical and Occupational Therapy in Pediatrics, 2010, 30, 43-53.	1.3	13
87	Neurophysiological profile of peripheral neuropathy associated with childhood mitochondrial disease. Mitochondrion, 2016, 30, 162-167.	3.4	13
88	Gait and footwear in children and adolescents with Charcot-Marie-Tooth disease: A cross-sectional, case-controlled study. Gait and Posture, 2018, 62, 262-267.	1.4	13
89	A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. Journal of Neuromuscular Diseases, 2021, 8, 769-784.	2.6	13
90	Juvenile polymyositis or paediatric muscular dystrophy: a detailed reâ€analysis of 13 cases. Histopathology, 2009, 55, 452-462.	2.9	12

#	Article	IF	Citations
91	Pediatric sciatic neuropathy associated with neoplasms. Muscle and Nerve, 2011, 43, 183-188.	2.2	12
92	X-linked Recessive Distal Myopathy With Hypertrophic Cardiomyopathy Caused by a Novel Mutation in the FHL1 Gene. Journal of Child Neurology, 2015, 30, 1211-1217.	1.4	12
93	Pathogenic mechanisms underlying X-linked Charcot-Marie-Tooth neuropathy (CMTX6) in patients with a pyruvate dehydrogenase kinase 3 mutation. Neurobiology of Disease, 2016, 94, 237-244.	4.4	12
94	242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1â€“3 March 2019. Neuromuscular Disorders, 2020, 30, 254-264.	0.6	12
95	Physical activity of children and adolescents with Charcot-Marie-Tooth neuropathies: A cross-sectional case-controlled study. PLoS ONE, 2019, 14, e0209628.	2.5	11
96	Muscle cramp in pediatric Charcot-Marie-Tooth disease type 1A. Neurology, 2011, 77, 2115-2118.	1.1	10
97	Physical activity and the use of standard and complementary therapies in Duchenne and Becker muscular dystrophies. Journal of Pediatric Rehabilitation Medicine, 2016, 9, 55-63.	0.5	10
98	Falls in paediatric Charcot-Marie-Tooth disease: a 6-month prospective cohort study. Archives of Disease in Childhood, 2019, 104, 535-540.	1.9	10
99	Benefits of powered standing wheelchair devices for adolescents with Duchenne muscular dystrophy in the first year of use. Journal of Paediatrics and Child Health, 2020, 56, 1419-1425.	0.8	10
100	Pathogenic deep intronic MTM1 variant activates a pseudo-exon encoding a nonsense codon resulting in severe X-linked myotubular myopathy. European Journal of Human Genetics, 2021, 29, 61-66.	2.8	10
101	Gaining consent for publication in difficult cases involving children. BMJ: British Medical Journal, 2008, 337, a1231-a1231.	2.3	10
102	Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 530-538.	1.9	10
103	Establishment of the Australasian paediatric Charcot-Marie-Tooth disease registry. Neuromuscular Disorders, 2007, 17, 349-350.	0.6	9
104	Mobile arm supports in Duchenne muscular dystrophy: a pilot study of user experience and outcomes. Disability and Rehabilitation: Assistive Technology, 2021, 16, 880-889.	2.2	9
105	Scientific rationale for a higher dose of nusinersen. Annals of Clinical and Translational Neurology, 2022, 9, 819-829.	3.7	9
106	Can in-the-moment diary methods measure health-related quality of life in Duchenne muscular dystrophy?. Quality of Life Research, 2017, 26, 1145-1152.	3.1	8
107	Atypical childhood chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2010, 42, 293-295.	2.2	7
108	Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscular Disorders, 2016, 26, 462-471.	0.6	7

#	Article	IF	Citations
109	Therapeutic Options to Improve Bone Health Outcomes in Duchenne Muscular Dystrophy: Zoledronic Acid and Pubertal Induction. Journal of Paediatrics and Child Health, 2017, 53, 1247-1248.	0.8	7
110	Dejerineâ€“Sottas disease in childhoodâ€”Genetic and sonographic heterogeneity. Brain and Behavior, 2018, 8, e00919.	2.2	7
111	Delivering multidisciplinary neuromuscular care for children via telehealth. Muscle and Nerve, 2022, 66, 31-38.	2.2	7
112	Respiration-Related Laryngeal Electromyography in Children with Bilateral Vocal Fold Paralysis. Annals of Otology, Rhinology and Laryngology, 2010, 119, 791-795.	1.1	5
113	Extended treatment of childhood Charcotâ€Marieâ€Tooth disease with highâ€dose ascorbic acid. Journal of the Peripheral Nervous System, 2011, 16, 272-274.	3.1	5
114	Spontaneous Intracranial Hypotension in Childhood: A Case Report and Review of the Literature. Journal of Child Neurology, 2011, 26, 761-766.	1.4	5
115	Carpal Tunnel Syndrome Secondary to Ganglion Cyst in a Child. Journal of Child Neurology, 2011, 26, 630-633.	1.4	5
116	Neuromuscular complications of intensive care. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1481-1483.	1.8	5
117	Cerebral palsy is not a diagnosis: A case report of a novel atlastinâ€1 mutation. Journal of Paediatrics and Child Health, 2016, 52, 669-671.	0.8	5
118	Investigation of the activation of the temporalis and masseter muscles in voluntary and spontaneous smile production. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2018, 71, 1051-1057.	1.0	5
119	The effects of calf massage in boys with Duchenne muscular dystrophy: a prospective interventional study. Disability and Rehabilitation, 2021, 43, 3803-3809.	1.8	5
120	Biallelic Variants in PYROXD2 Cause a Severe Infantile Metabolic Disorder Affecting Mitochondrial Function. International Journal of Molecular Sciences, 2022, 23, 986.	4.1	5
121	Neurophysiologic findings in children presenting with pes cavus. Journal of the Peripheral Nervous System, 2010, 15, 238-240.	3.1	4
122	Evaluation of Serial Casting for Boys with Duchenne Muscular Dystrophy: A Case Report. Physical and Occupational Therapy in Pediatrics, 2018, 38, 88-96.	1.3	4
123	Peripheral nerve disease secondary to systemic conditions in children. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641986636.	3.5	4
124	Distinct effects on mRNA export factor GANP underlie neurological disease phenotypes and alter gene expression depending on intron content. Human Molecular Genetics, 2020, 29, 1426-1439.	2.9	4
125	Effect of a multicomponent nutritional supplement on functional outcomes for Duchenne muscular dystrophy: A randomized controlled trial. Clinical Nutrition, 2021, 40, 4702-4711.	5.0	4
126	Juvenile Parkinsonism. Journal of Paediatrics and Child Health, 2013, 49, 409-411.	0.8	3

#	Article	IF	Citations
127	Unique clinical and neurophysiologic profile of a cohort of children with CMTX3. Neurology, 2018, 90, e1706-e1710.	1.1	3
128	Infantile-Onset Myelin Protein Zeroâ€“Related Demyelinating Neuropathy Presenting as an Upper Extremity Monoplegia. Seminars in Pediatric Neurology, 2018, 26, 52-55.	2.0	3
129	Communication about spinal muscular atrophy and genetic risk within families: An Australian pilot study. Journal of Paediatrics and Child Health, 2020, 56, 1263-1269.	0.8	3
130	Generating an iPSC line (with isogenic control) from the PBMCs of an ACTA1 (p.Gly148Asp) nemaline myopathy patient. Stem Cell Research, 2021, 54, 102429.	0.7	3
131	Guillainâ€“BarrÃ© syndrome with optic neuritis. Journal of Paediatrics and Child Health, 2022, 58, 887-890.	0.8	3
132	Gene therapy for neuromuscular disorders: prospects and ethics. Archives of Disease in Childhood, 2022, 107, 421-426.	1.9	3
133	The association between dietary factors and body weight and composition in boys with Duchenne muscular dystrophy. Journal of Human Nutrition and Dietetics, 2022, 35, 804-815.	2.5	3
134	Overview of Pediatric Peripheral Neuropathies. , 2015, , 274-288.		2
135	Neurologic Melioidosis: Case Report of a Rare Cause of Acute Flaccid Paralysis. Journal of Pediatrics, 2016, 170, 319-321.	1.8	2
136	Cerebellar ataxia with normal intellect associated with a homozygous truncating variant in CA8. Clinical Genetics, 2020, 97, 516-520.	2.0	2
137	VENLAFAXINE INGESTION IN A 4â€YEARâ€OLD GIRL. Journal of Paediatrics and Child Health, 2012, 48, 1047-1048.	0.8	1
138	A family with 2 X-linked disorders: Charcot-Marie-Tooth disease and hemophilia A. Muscle and Nerve, 2012, 46, 454-455.	2.2	1
139	Mononeuropathies. , 2015, , 243-273.		0
140	Acute Polyneuropathies. , 2015, , 379-397.		0
141	Disorders of the Ocular Motor Cranial Nerves and Extraocular Muscles. , 2015, , 922-957.		0
142	Authors' Response to Commentary. Journal of Pediatric Rehabilitation Medicine, 2016, 9, 77.	0.5	0
143	Fifty years of paediatric neurology in Australasia. Journal of Paediatrics and Child Health, 2016, 52, 861-864.	0.8	0
144	Comment on: Paediatric Facial Paralysis: An overview and Insights into Management. Journal of Paediatrics and Child Health, 2021, 57, 1725-1725.	0.8	0

#	Article	IF	Citations
145	Characterising gait in paediatric neuromuscular disorders: an observational study of spatio-temporal gait in a clinical cohort. Disability and Rehabilitation, 2021, , 1-7.	1.8	0